Header Logo

Connection

THOMAS LLOYD to Hydroxylamines

Back to Details
This is a "connection" page, showing publications THOMAS LLOYD has written about Hydroxylamines.
THOMAS LLOYD
Connection Strength
0.052
Hydroxylamines
  1. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.